These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 9174683)
1. Cerebrospinal fluid and plasma disposition of yohimbine and 11-hydroxy-yohimbine in young and older healthy subjects, and Alzheimer's disease patients. Le Corre PA; Peskind ER; Chevanne F; Raskind MA; Le Verge R Eur J Clin Pharmacol; 1997; 52(2):135-8. PubMed ID: 9174683 [TBL] [Abstract][Full Text] [Related]
2. Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Peskind ER; Wingerson D; Murray S; Pascualy M; Dobie DJ; Le Corre P; Le Verge R; Veith RC; Raskind MA Arch Gen Psychiatry; 1995 Sep; 52(9):774-82. PubMed ID: 7654129 [TBL] [Abstract][Full Text] [Related]
3. Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. Raskind MA; Peskind ER; Holmes C; Goldstein DS Biol Psychiatry; 1999 Sep; 46(6):756-65. PubMed ID: 10494443 [TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid epinephrine in Alzheimer's disease and normal aging. Peskind ER; Elrod R; Dobie DJ; Pascualy M; Petrie E; Jensen C; Brodkin K; Murray S; Veith RC; Raskind MA Neuropsychopharmacology; 1998 Dec; 19(6):465-71. PubMed ID: 9803422 [TBL] [Abstract][Full Text] [Related]
5. Biopharmaceutics and metabolism of yohimbine in humans. Le Corre P; Dollo G; Chevanne F; Le Verge R Eur J Pharm Sci; 1999 Oct; 9(1):79-84. PubMed ID: 10494000 [TBL] [Abstract][Full Text] [Related]
6. Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Le Corre P; Parmer RJ; Kailasam MT; Kennedy BP; Skaar TP; Ho H; Leverge R; Smith DW; Ziegler MG; Insel PA; Schork NJ; Flockhart DA; O'connor DT Clin Pharmacol Ther; 2004 Aug; 76(2):139-53. PubMed ID: 15289791 [TBL] [Abstract][Full Text] [Related]
7. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Rasmusson AM; Hauger RL; Morgan CA; Bremner JD; Charney DS; Southwick SM Biol Psychiatry; 2000 Mar; 47(6):526-39. PubMed ID: 10715359 [TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship of yohimbine and its related analogs in blocking alpha-1 and alpha-2 adrenoceptors: a comparative study of cardiovascular activities. Ito Y; Yano S; Watanabe K; Yamanaka E; Aimi N; Sakai S Chem Pharm Bull (Tokyo); 1990 Jun; 38(6):1702-6. PubMed ID: 1976443 [TBL] [Abstract][Full Text] [Related]
9. Aging and Alzheimer's disease: protease inhibitors in cerebrospinal fluid. Delamarche C; Berger F; Gallard L; Pouplard-Barthelaix A Neurobiol Aging; 1991; 12(1):71-4. PubMed ID: 2002886 [TBL] [Abstract][Full Text] [Related]
10. Plasma MHPG response to yohimbine treatment in women with hypoactive sexual desire. Piletz JE; Segraves KB; Feng YZ; Maguire E; Dunger B; Halaris A J Sex Marital Ther; 1998; 24(1):43-54. PubMed ID: 9509380 [TBL] [Abstract][Full Text] [Related]
11. Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. Basun H; Forssell LG; Wetterberg L; Winblad B J Neural Transm Park Dis Dement Sect; 1991; 3(4):231-58. PubMed ID: 1772577 [TBL] [Abstract][Full Text] [Related]
12. Yohimbine increases cerebrospinal fluid and plasma norepinephrine but not arginine vasopressin in humans. Peskind ER; Veith RC; Dorsa DM; Gumbrecht G; Raskind MA Neuroendocrinology; 1989 Sep; 50(3):286-91. PubMed ID: 2552342 [TBL] [Abstract][Full Text] [Related]
13. Variations in circulating catecholamines fail to alter human platelet alpha-2-adrenergic receptor number or affinity for [3H]yohimbine or [3H]dihydroergocryptine. Pfeifer MA; Ward K; Malpass T; Stratton J; Halter J; Evans M; Beiter H; Harker LA; Porte D J Clin Invest; 1984 Sep; 74(3):1063-72. PubMed ID: 6088579 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular reactivity to mental stress is not affected by alpha2-adrenoreceptor activation or inhibition. Philippsen C; Hahn M; Schwabe L; Richter S; Drewe J; Schachinger H Psychopharmacology (Berl); 2007 Feb; 190(2):181-8. PubMed ID: 17111173 [TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid corticotropin-releasing hormone in healthy humans: effects of yohimbine and naloxone. Vythilingam M; Anderson GM; Owens MJ; Halaszynski TM; Bremner JD; Carpenter LL; Heninger GR; Nemeroff CB; Charney DS J Clin Endocrinol Metab; 2000 Nov; 85(11):4138-45. PubMed ID: 11095445 [TBL] [Abstract][Full Text] [Related]
16. Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine. Krystal JH; McDougle CJ; Woods SW; Price LH; Heninger GR; Charney DS Psychopharmacology (Berl); 1992; 108(3):313-9. PubMed ID: 1355923 [TBL] [Abstract][Full Text] [Related]
17. Involvement of muscarinic cholinergic and alpha2-adrenergic mechanisms in growth hormone secretion during exercise in humans. Harada T; Yamauchi T; Tsukanaka A; Matsumura Y; Kurono M; Honda A; Matsui N Eur J Appl Physiol; 2000 Nov; 83(4 -5):268-73. PubMed ID: 11138563 [TBL] [Abstract][Full Text] [Related]
18. Increased plasma norepinephrine response to yohimbine in elderly men. Petrie EC; Peskind ER; Dobie DJ; Veith RC; Raskind MA J Gerontol A Biol Sci Med Sci; 2000 Mar; 55(3):M155-9. PubMed ID: 10795728 [TBL] [Abstract][Full Text] [Related]
19. Plasma neuropeptide Y (NPY) increases in humans in response to the alpha 2 antagonist yohimbine. Rasmusson AM; Southwick SM; Hauger RL; Charney DS Neuropsychopharmacology; 1998 Jul; 19(1):95-8. PubMed ID: 9608581 [TBL] [Abstract][Full Text] [Related]
20. Effect of the alpha 2-adrenergic antagonist yohimbine on orthostatic tolerance. Farrow S; Mers A; Banta G; Steigerwalt S; Lockette W Hypertension; 1990 Jun; 15(6 Pt 2):877-80. PubMed ID: 1972139 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]